Generic Name and Formulations:
Bimatoprost 0.03%; oph soln; contains benzalkonium chloride.
Indications for LATISSE:
Hypotrichosis of the eyelashes.
1 drop once nightly; apply evenly along upper eyelid skin margin at the base of eyelashes. Repeat for opposite eyelid margin with new sterile applicator. Blot any excess solution runoff.
Do not apply to lower eyelash line. Repeated contact with bimatoprost outside the treatment area may cause hair growth. Ocular hypertension; monitor for changes to intraocular pressure. Ocular inflammation (eg, uveitis). Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Contact lenses (remove; may reinsert lenses 15 minutes after administration). Pregnancy (Cat.C). Nursing mothers.
Concomitant with other intraocular pressure (IOP)-lowering prostaglandin analogues may decrease IOP-lowering effects.
Eye pruritus, conjunctival hyperemia, increased ocular pigmentation (iris, eyelid; may be permanent), ocular irritation, dry eye, erythema of the eyelid, macular edema, abnormal hair growth.
Soln—3mL (w. disposable sterile applicators)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC